Effects of a selective iNOS inhibitor versus norepinephrine in the treatment of septic shock

Shock

Volumn 34, Issue 3, 2010, Pages 243-249

  Su, Fuhong ^a   Huang, Hongchuan ^a   Akieda, Kazuki ^a   Occhipinti, Giovanna ^a   Donadello, Katia ^a   Piagnerelli, Michael ^a   De Backer, Daniel ^a   Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

arterial blood pressure; microcirculation; Nitric oxide; NOS; renal blood flow

Indexed keywords

2 [2 (4 METHOXYPYRIDIN 2 YL)ETHYL] 3H IMIDAZO [4,5 B]PYRIDINE; BYK 191023; INDUCIBLE NITRIC OXIDE SYNTHASE; LACTIC ACID; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL VENTILATION; CAPILLARY DENSITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SELECTIVITY; ENZYME INHIBITION; FEMALE; HEART INDEX; KIDNEY BLOOD FLOW; LUNG ARTERY PRESSURE; LUNG GAS EXCHANGE; MESENTERY BLOOD FLOW; MICROCIRCULATION; MICROSCOPY; NONHUMAN; OXYGEN TENSION; PERITONITIS; SEPTIC SHOCK; SHEEP; SURVIVAL TIME; SYSTEMIC VASCULAR RESISTANCE;

ANIMALS; DRUG EVALUATION, PRECLINICAL; FEMALE; IMIDAZOLES; LACTATES; MODELS, ANIMAL; NITRIC OXIDE SYNTHASE TYPE II; NOREPINEPHRINE; PERITONITIS; PULMONARY GAS EXCHANGE; PULMONARY WEDGE PRESSURE; PYRIDINES; RANDOM ALLOCATION; RENAL CIRCULATION; SHEEP; SHOCK, SEPTIC; SPLANCHNIC CIRCULATION;

EID: 77955958738     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181d75967     Document Type: Article

References (46)

1. Christaki E, Opal SM: Is the mortality rate for septic shock really decreasing? Curr Opin Crit Care 14:580-586, 2008.
2. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 329:2002-2012, 1993.
3. Barth E, Radermacher P, Thiemermann C, Weber S, Georgieff M, Albuszies G: Role of inducible nitric oxide synthase in the reduced responsiveness of the myocardium to catecholamines in a hyperdynamic, murine model of septic shock. Crit Care Med 34:307-313, 2006.
4. Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, et al.: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32:21-30, 2004.
5. Salerno L, Sorrenti V, Di Giacomo C, Romeo G, Siracusa MA: Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr Pharm Des 8:177-200, 2002.
6. Johannes T, Mik EG, Klingel K, Goedhart PT, Zanke C, Nohe B, Dieterich HJ, Unertl KE, Ince C: Effects of 1400W and/or nitroglycerin on renal oxygen-ation and kidney function during endotoxaemia in anaesthetised rats. Clin Exp Pharmacol Physiol 2009 Apr 27. [Epub ahead of print].
7. Cuzzocrea S, Mazzon E, Di Paola R, Esposito E, Macarthur H, Matuschak GM, Salvemini D: A role for nitric oxide-mediated peroxynitrite formation in a model of endotoxin-induced shock. J Pharmacol Exp Ther 319:73-81, 2006.
8. Xie XQ, Shinozawa Y, Sasaki J, Takuma K, Akaishi S, Yamanouchi S, Endo T, Nomura R, Kobayashi M, Kudo D, et al.: The effects of arginine and selective inducible nitric oxide synthase inhibitor on pathophysiology of sepsis in a CLP model. J Surg Res 146:298-303, 2008.
9. Matejovic M, Krouzecky A, Radej J, Rokyta R Jr, Kralova H, Radermacher P, Novak I: Coagulation and endothelial dysfunction during longterm hyper-dynamic porcine bacteremiaVeffects of selective inducible nitric oxide syn-thase inhibition. Thromb Haemost 97:304-309, 2007.
10. Cobb JP, Hotchkiss RS, Swanson PE, Chang K, Qiu Y, Laubach VE, Karl IE, Buchman TG: Inducible nitric oxide synthase (iNOS) gene deficiency increases the mortality of sepsis in mice. Surgery 126:438-442, 1999.
11. Gunnett CA, Chu Y, Heistad DD, Loihl A, Faraci FM: Vascular effects of LPS in mice deficient in expression of the gene for inducible nitric oxide synthase. Am J Physiol 275:H416-H421, 1998.
12. Nicholson SC, Grobmyer SR, Shiloh MU, Brause JE, Potter S, MacMicking JD, Dinauer MC, Nathan CF: Lethality of endotoxin in mice genetically deficient in the respiratory burst oxidase, inducible nitric oxide synthase, or both. Shock 11:253-258, 1999.
13. Wei XQ, Charles IG, Smith A, Ure J, Feng GJ, Huang FP, Xu D, Muller W, Moncada S, Liew FY: Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375:408-411, 1995.
14. Takakura K, Taniguchi T, Muramatsu I, Takeuchi K, Fukuda S: Modification of alpha1-adrenoceptors by peroxynitrite as a possible mechanism of systemic hypotension in sepsis. Crit Care Med 30:894-899, 2002.
15. Avontuur JA, Bruining HA, Ince C: Sepsis and nitric oxide. Adv Exp Med Biol 388:551-567, 1996.
16. Hesslinger C, Strub A, Boer R, Ulrich WR, Lehner MD, Braun C: Inhibition of inducible nitric oxide synthase in respiratory diseases. Biochem Soc Trans 37:886-891, 2009.
17. Tinker AC, Wallace AV: Selective inhibitors of inducible nitric oxide synthase: potential agents for the treatment of inflammatory diseases? Curr Top Med Chem 6:77-92, 2006.
18. Willmot M, Gibson C, Gray L, Murphy S, Bath P: Nitric oxide synthase inhibitors in experimental ischemic stroke and their effects on infarct size and cerebral blood flow: a systematic review. Free Radic Biol Med 39:412-425, 2005.
19. Strub A, Ulrich WR, Hesslinger C, Eltze M, Fuchss T, Strassner J, Strand S, Lehner MD, Boer R: The novel imidazopyridine 2-[2-(4-methoxy-pyridin-2-yl)- ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) is a highly selective inhibitor of the inducible nitric-oxide synthase. Mol Pharmacol 69:328-337, 2006.
20. Tiso M, Strub A, Hesslinger C, Kenney CT, Boer R, Stuehr DJ: BYK191023 (2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3h-imidazo[4,5-b]pyridine) is an N. Mol Pharmacol 73:1244-1253, 2008.
21. Lehner MD, Marx D, Boer R, Strub A, Hesslinger C, Eltze M, Ulrich WR, Schwoebel F, Schermuly RT, Barsig J: In vivo characterization of the novel imidazopyridine BYK191023 [2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5- b]pyridine], a potent and highly selective inhibitor of in-ducible nitric-oxide synthase. J Pharmacol Exp Ther 317:181-187, 2006.
22. Ince C: The microcirculation is the motor of sepsis. Crit Care 9:S13-S19, 2005.
23. De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL: Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 166: 98-104, 2002.
24. De Backer D, Hollenberg S, Boerma C, Goedhart P, Buchele G, Ospina-Tascon G, Dobbe I, Ince C: How to evaluate the microcirculation: report of a round table conference. Crit Care 11:R101, 2007.
25. Su F, Brands R, Wang Z, Verdant C, Bruhn A, Cai Y, Raaben W, Wulferink M, Vincent JL: Beneficial effects of alkaline phosphatase in septic shock. Crit Care Med 34:2182-2187, 2006.
26. Stoclet JC, Muller B, Gyorgy K, Andriantsiothaina R, Kleschyov AL: The inducible nitric oxide synthase in vascular and cardiac tissue. Eur J Pharmacol 375:139-155, 1999.
27. Boyle WA III, Parvathaneni LS, Bourlier V, Sauter C, Laubach VE, Cobb JP: iNOS gene expression modulates microvascular responsiveness in endotoxin-challenged mice. Circ Res 87:E18-E24, 2000.
28. Ichinose F, Hataishi R, Wu JC, Kawai N, Rodrigues AC, Mallari C, Post JM, Parkinson JF, Picard MH, Bloch KD, et al.: A selective inducible NOS dimerization inhibitor prevents systemic, cardiac, and pulmonary hemody-namic dysfunction in endotoxemic mice. Am J Physiol Heart Circ Physiol 285:H2524-H2530, 2003.
29. Enkhbaatar P, Murakami K, Shimoda K, Mizutani A, Traber L, Phillips G, Parkinson J, Salsbury JR, Biondo N, Schmalstieg F, et al.: Inducible nitric oxide synthase dimerization inhibitor prevents cardiovascular and renal morbidity in sheep with combined burn and smoke inhalation injury. Am J Physiol Heart Circ Physiol 285:H2430-H2436, 2003.
30. Ogasawara H, Koizumi T, Yamamoto H, Kubo K: Effects of a selective nitric oxide synthase inhibitor on endotoxin-induced alteration in hypoxic pulmonary vasoconstriction in sheep. J Cardiovasc Pharmacol 42:521-526, 2003.
31. Mikawa K, Nishina K, Takao Y, Obara H: ONO-1714, a nitric oxide synthase inhibitor, attenuates endotoxin-induced acute lung injury in rabbits. Anesth Analg 97:1751-1755, 2003.
32. Enkhbaatar P, Murakami K, Traber LD, Cox R, Parkinson JF, Westphal M, Esechie A, Morita N, Maybauer MO, Maybauer DM, et al.: The inhibition of inducible nitric oxide synthase in ovine sepsis model. Shock 25:522-527, 2006.
33. Soejima K, McGuire R, Snyder N, Uchida T, Szabo C, Salzman A, Traber LD, Traber DL: The effect of inducible nitric oxide synthase (iNOS) inhibition on smoke inhalation injury in sheep. Shock 13:261-266, 2000.
34. Lange M, Connelly R, Traber DL, Hamahata A, Cox RA, Nakano Y, Bansal K, Esechie A, von Borzyskowski S, Jonkam C, et al.: Combined neuronal and inducible nitric oxide synthase inhibition in ovine acute lung injury. Crit Care Med 37:223-229, 2009.
35. Heemskerk S, Pickkers P, Bouw MP, Draisma A, van der Hoeven JG, Peters WH, Smits P, Russel FG, Masereeuw R: Upregulation of renal inducible nitric oxide synthase during human endotoxemia and sepsis is associated with proximal tubule injury. Clin J Am Soc Nephrol 1:853-862, 2006.
36. Schrier RW, Wang W: Acute renal failure and sepsis. N Engl J Med 351: 159-169, 2004.
37. Wu L, Mayeux PR: Effects of the inducible nitric-oxide synthase inhibitor L-N(6)-(1-iminoethyl)-lysine on microcirculation and reactive nitrogen species generation in the kidney following lipopolysaccharide administration in mice. J Pharmacol Exp Ther 320:1061-1067, 2007.
38. Matejovic M, Krouzecky A, Martinkova V, Rokyta R Jr, Kralova H, Treska V, Radermacher P, Novak I: Selective inducible nitric oxide synthase inhibition during long-term hyperdynamic porcine bacteremia. Shock 21: 458-465, 2004.
39. De Souza DA, Greene LJ: Intestinal permeability and systemic infections in critically ill patients: effect of glutamine. Crit Care Med 33:1125-1135, 2005.
40. Krejci V, Hiltebrand LB, Sigurdsson GH: Effects of epinephrine, norepinephr-ine, and phenylephrine on microcirculatory blood flow in the gastrointestinal tract in sepsis. Crit Care Med 34:1456-1463, 2006.
41. 2 balance during endotoxemia in pigs. Intensive Care Med 31:985-992, 2005.
42. Lush CW, Kvietys PR: Microvascular dysfunction in sepsis. Microcirculation 7:83-101, 2000.
43. Revelly JP, Liaudet L, Frascarolo P, Joseph JM, Martinet O, Markert M: Effects of norepinephrine on the distribution of intestinal blood flow and tissue adenosine triphosphate content in endotoxic shock. Crit Care Med 28: 2500-2506, 2000.
44. Kan WH, Hsu JT, Schwacha MG, Choudhry MA, Raju R, Bland KI, Chaudry IH: Selective inhibition of iNOS attenuates trauma-hemorrhage/resuscitation-induced hepatic injury. J Appl Physiol 105:1076-1082, 2008.
45. Jian MY, Koizumi T, Kubo K: Effects of nitric oxide synthase inhibitor on acid aspiration-induced lung injury in rats. Pulm Pharmacol Ther 18:33-39, 2005.
46. Okamoto I, Abe M, Shibata K, Shimizu N, Sakata N, Katsuragi T, Tanaka K: Evaluating the role of inducible nitric oxide synthase using a novel and selective inducible nitric oxide synthase inhibitor in septic lung injury produced by cecal ligation and puncture. Am J Respir Crit Care Med 162: 716-722, 2000.